Search research articles
Contact Us
Filters
Showing results (21-30 of 88) with videos related to
Page
of 9
Sort By:
Leukemia & Lymphoma
|
August 20, 2020
Updated safety of midostaurin plus chemotherapy in newly diagnosed <i>FLT3</i> mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program
Gail J Roboz, Stephen A Strickland, Mark R Litzow, et al.
Journal of the American Academy of Dermatology
|
November 7, 2017
Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center
Caroline A Nelson, Megan H Noe, Christine M McMahon, et al.
American Journal of Hematology
|
May 4, 2013
Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens
Daniel J Landsburg, Edward Stadtmauer, Alison Loren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2018
Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors
Gregory W Schwartz, Bryan Manning, Yeqiao Zhou, et al.
Blood
|
June 8, 2018
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AML
Jorge E Cortes, Martin S Tallman, Gary J Schiller, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 5, 2025
Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
Hetty E Carraway, Andrew M Brunner, Catherine E Lai, et al.
Blood Advances
|
April 13, 2018
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with <i>FLT3</i>-ITD mutations
Mark J Levis, Alexander E Perl, Jessica K Altman, et al.
The Journal of Clinical Investigation
|
March 20, 2020
Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL
Christian Hurtz, Gerald B Wertheim, Joseph P Loftus, et al.
Clinical Pharmacokinetics
|
April 19, 2020
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Angela Joubert James, Catherine C Smith, Mark Litzow, et al.
Transplantation and Cellular Therapy
|
October 5, 2020
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
Siddhartha Ganguly, Jorge E Cortes, Alwin Krämer, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 88) with videos related to
Sort By:
Page
of 9
Leukemia & Lymphoma
|
August 20, 2020
Updated safety of midostaurin plus chemotherapy in newly diagnosed <i>FLT3</i> mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program
Gail J Roboz, Stephen A Strickland, Mark R Litzow, et al.
Journal of the American Academy of Dermatology
|
November 7, 2017
Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center
Caroline A Nelson, Megan H Noe, Christine M McMahon, et al.
American Journal of Hematology
|
May 4, 2013
Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens
Daniel J Landsburg, Edward Stadtmauer, Alison Loren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2018
Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors
Gregory W Schwartz, Bryan Manning, Yeqiao Zhou, et al.
Blood
|
June 8, 2018
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AML
Jorge E Cortes, Martin S Tallman, Gary J Schiller, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 5, 2025
Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
Hetty E Carraway, Andrew M Brunner, Catherine E Lai, et al.
Blood Advances
|
April 13, 2018
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with <i>FLT3</i>-ITD mutations
Mark J Levis, Alexander E Perl, Jessica K Altman, et al.
The Journal of Clinical Investigation
|
March 20, 2020
Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL
Christian Hurtz, Gerald B Wertheim, Joseph P Loftus, et al.
Clinical Pharmacokinetics
|
April 19, 2020
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Angela Joubert James, Catherine C Smith, Mark Litzow, et al.
Transplantation and Cellular Therapy
|
October 5, 2020
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
Siddhartha Ganguly, Jorge E Cortes, Alwin Krämer, et al.
Page
of 9